Description: Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Its lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers and in preclinical studies for triple negative and inflammatory breast cancers. The company's other drug candidate, Liposomal Bcl-2, is ready for the clinic where it would be evaluated in lymphoma and solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.
Home Page: www.biopathholdings.com
BPTH Technical Analysis
4710 Bellaire Boulevard
Bellaire,
TX
77401
United States
Phone:
832 742 1357
Officers
| Name | Title |
|---|---|
| Mr. Peter H. Nielsen MBA | Co-Founder, Chairman, CEO, Pres, CFO & Treasurer |
| Mr. Douglas P. Morris | Co-Founder, Director of Investor Relations, Sec. & Director |
| Mr. Anthony Price | Sr. VP of Fin., Accounting & Admin. |
| Dr. Ana Tari Ashizawa Ph.D., MBA | Sr. VP of Research, Devel. & Clinical Design |
| Dr. Alan MacKenzie Ph.D. | Consultant |
| Dr. Thomas A. Walker Ph.D. | Consultant |
| Dr. Jeffery Lancet M.D. | Consultant |
| Ms. Victoria Lake Rac | Regulatory Consultant |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7618 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2008-03-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 10 |